초록
새로운 항균제 및 항종양제를 합성하기 위하여 norfloxacin(8) 또는 ciprofloxacin(9)이 pteroic acid의 C-9위치에 치환되고 C-2 위치에 아미노기 대신 $CH_3$기가 치환된 새로운 pteroic acid 유도체 13a와 13b를 합성하였다. 이는 출발 물질인 norfloxacin과 ciprofloxacin의 piperazine N-4 위치에 2-amino-3-cyano-5-chloro-methylpyrazine(20)을 결합하여 1-alkyl(ethyl, cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-7-[[4-N- (2-amino-3-cyanopyrazin-5-yl)methyl]piperazin-1-yl]-3-quinolinecarboxytic acid(12a, 12b)를 합성하였다. 이를 각각 acetamidine. HCl과 고리화시켜 C-2 위치에 아미노기 대신 $CH_3$기가 치환된 새로운 pteroic acid 유도체 135와 13b를 각각 76.2%와 82.8%의 수율로 합성하였다. 그리고 이들 화합물에 대한 항균활성의 측정은 Pseudomonas aeruginosa ATCC9027을 포함하여 Gram-positive와 Gram-negative bacteria에 대하여 검토한 결과 합성한 화합물 13a와 13b는 일반적으로 norfloxacin보다 낮은 항균활성을 나타냈다.
In order to synthesize a new antibacterial and antitumor agents, we have prepared new analogues pteroic acid(13a, 13b), which means C-9 position of pteroic acid has been replaced by norfloxacin(8) or ciprofloxacin(9) and amino group of C-2 position by $CH_3$. These derivatives were synthesized coupling at N-4 piperazine of norfloxacin and ciprofloxacin with 2-amino-3-cyano-5-chloromethylpyrazine(20) provided 1-alkyl(ethyl, cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-7-[[4-N-(2-amino-3-cyanopyrazin-5-yl)methyl]piperazin-1-yl]-3-quinoline-carboxylic acid(12a, 12b). It was then cyclized with acetamidine. HCI to obtain new analogues of C-2 desaminomethylpteroic acid(13a, 13b) in yield of 76.2% and 82.8 % respectively. These compounds were tested in vitro on antibacterial activity against Gram-positive and Gram-negative bacteria including Pseudomonas aeruginosa ATCC9027. In general, these synthesized compounds(13a, 13b) showed less potent activities than those of norfloxacin.